

ENDOLOGIX INC /DE/  
Form 10-Q  
November 01, 2012  
Table of Contents

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549

---

FORM 10-Q

---

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2012.

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from \_\_\_\_\_ to \_\_\_\_\_  
Commission file number 000-28440

---

ENDOLOGIX, INC.  
(Exact name of registrant as specified in its charter)

---

|   |  |
|---|--|
| Delaware<br>(State or other jurisdiction of<br>incorporation or organization)       | 68-0328265<br>(I.R.S. Employer<br>Identification Number) |
| 11 Studebaker, Irvine, California 92618<br>(Address of principal executive offices) |  |
| (949) 595-7200<br>(Registrant's telephone number, including area code)              |  |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

|                         |  |                           |                                     |
|-------------------------|--|---------------------------|-------------------------------------|
| Large accelerated filer | <input type="checkbox"/>   | Accelerated filer         | <input checked="" type="checkbox"/> |
| Non-accelerated filer   | <input type="checkbox"/> (Do not check if a smaller reporting company) | Smaller reporting company | <input type="checkbox"/>            |

Table of Contents

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

On October 25, 2012, there were 61,956,530 shares outstanding of the registrant's only class of common stock.

---

Table of Contents

ENDOLOGIX, INC.  
QUARTERLY REPORT ON FORM 10-Q

TABLE OF CONTENTS

|   | Page      |
|---|-----------|
| <u>Part I. Financial Information</u>  |           |
| Item 1.   |           |
| <u>Condensed Consolidated Financial Statements (Unaudited):</u>   |           |
| <u>Condensed Consolidated Balance Sheets at September 30, 2012 and December 31, 2011</u>  | <u>3</u>  |
| <u>Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2012 and 2011</u> | <u>4</u>  |
| <u>Condensed Consolidated Statement of Cash Flows for the nine months ended September 30, 2012 and 2011</u>                                   | <u>5</u>  |
| <u>Notes to Condensed Consolidated Financial Statements</u>   | <u>6</u>  |
| Item 2.   |           |
| <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>  | <u>18</u> |
| Item 3.   |           |
| <u>Quantitative and Qualitative Disclosures About Market Risk</u>   | <u>27</u> |
| Item 4.   |           |
| <u>Controls and Procedures</u>  | <u>27</u> |
| <u>Part II. Other Information</u>   |           |
| Item 1.   |           |
| <u>Legal Proceedings</u>  | <u>29</u> |
| Item 6.   |           |
| <u>Exhibits</u>   | <u>29</u> |
| <u>Signatures</u>   |           |
| <u>29</u>   |           |
| <u>Exhibit Index</u>  |           |
| <u>29</u>   |           |

Table of Contents

ENDOLOGIX, INC.  
 CONDENSED CONSOLIDATED BALANCE SHEETS  
 (In thousands, except share and par value amounts)  
 (Unaudited)

|  | September 30,<br>2012 | December 31,<br>2011 |
|--|-----------------------|----------------------|
| <b>ASSETS</b>  |                       |                      |
| Current assets:  |                       |                      |
| Cash and cash equivalents  | \$47,740              | \$20,035             |
| Accounts receivable, net of allowance for doubtful accounts of \$224 and \$161, respectively.  | 19,616                | 15,542               |
| Other receivables  | 302                   | 405                  |
| Inventories  | 19,061                | 18,099               |
| Prepaid expenses and other current assets  | 1,579                 | 1,023                |
| Total current assets   | 88,298                | 55,104               |
| Property and equipment, net  | 4,951                 | 4,454                |
| Goodwill   | 28,969                | 27,073               |
| Intangibles, net   | 43,399                | 43,439               |
| Deposits and other assets  | 211                   | 185                  |
| Total assets   | \$165,828             | \$130,255            |
| <b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>  |                       |                      |
| Current liabilities:   |                       |                      |
| Accounts payable   | \$9,487               | \$6,377              |
| Accrued payroll  | 6,977                 | 6,569                |
| Accrued expenses and other current liabilities   | 2,264                 | 1,003                |
| Total current liabilities  | 18,728                | 13,949               |
| Deferred income taxes  | 1,029                 | 1,029                |
| Deferred rent  | —                     | 8                    |
| Contingently issuable common stock   | 51,400                | 38,700               |
| Total liabilities  | 71,157                | 53,686               |
| Commitments and contingencies  |                       |                      |
| Stockholders' equity:  |                       |                      |
| Convertible preferred stock, \$0.001 par value; 5,000,000 shares authorized. No shares issued and outstanding.   | —                     | —                    |
| Common stock, \$0.001 par value; 75,000,000 shares authorized. 62,365,676 and 58,577,484 shares issued, respectively. 61,870,976 and 58,082,784 shares issued and outstanding, respectively. | 62                    | 59                   |
| Additional paid-in capital   | 288,798               | 241,441              |
| Accumulated deficit  | (193,496              | ) (164,240           |
| Treasury stock, at cost, 494,700 shares  | (661                  | ) (661               |
| Accumulated other comprehensive loss   | (32                   | ) (30                |
| Total stockholders' equity   | 94,671                | 76,569               |
| Total liabilities and stockholders' equity   | \$165,828             | \$130,255            |
| The accompanying notes are an integral part of these financial statements  |                       |                      |



Table of Contents

## ENDOLOGIX, INC.

## CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(In thousands, except per share amounts)

(Unaudited)

|  | Three Months Ended<br>September 30, |            | Nine Months Ended<br>September 30, |             |
|--|-------------------------------------|------------|------------------------------------|-------------|
|  | 2012                                | 2011       | 2012                               | 2011        |
| Revenue  | \$26,696                            | \$22,302   | \$76,725                           | \$60,025    |
| Cost of goods sold   | 6,444                               | 4,829      | 18,148                             | 13,352      |
| Gross profit   | 20,252                              | 17,473     | 58,577                             | 46,673      |
| Operating expenses:  |                                     |            |                                    |             |
| Research and development   | 3,076                               | 3,628      | 11,886                             | 12,812      |
| Clinical and regulatory affairs  | 1,462                               | 1,179      | 4,727                              | 2,994       |
| Marketing and sales  | 12,705                              | 12,331     | 38,923                             | 33,201      |
| General and administrative   | 4,942                               | 4,184      | 13,813                             | 11,087      |
| Contract termination and business acquisition expenses                     | —                                   | 1,300      | 422                                | 1,730       |
| Settlement costs   | 5,000                               | —          | 5,000                              | —           |
| Total operating expenses   | 27,185                              | 22,622     | 74,771                             | 61,824      |
| Loss from operations   | (6,933                              | ) (5,149   | ) (16,194                          | ) (15,151   |
| Other income (expense):  |                                     |            |                                    |             |
| Interest income  | 34                                  | 3          | 24                                 | 19          |
| Interest expense   | —                                   | (19        | ) (3                               | ) (28       |
| Gain on sale of equipment  | —                                   | —          | —                                  | 141         |
| Other expense, net   | (101                                | ) (38      | ) (86                              | ) (45       |
| Change in fair value of contingent consideration<br>related to acquisition | 990                                 | (1,400     | ) (12,700                          | ) (10,000   |
| Total other income (expense)   | 923                                 | (1,454     | ) (12,765                          | ) (9,913    |
| Net loss before income tax expense   | \$(6,010                            | ) \$(6,603 | ) \$(28,959                        | ) \$(25,064 |
| Income tax (expense) benefit   | 153                                 | —          | (297                               | ) —         |
| Net loss   | \$(5,857                            | ) \$(6,603 | ) \$(29,256                        | ) \$(25,064 |
| Basic and diluted net loss per share                                       | \$(0.10                             | ) \$(0.12  | ) \$(0.49                          | ) \$(0.44   |
| Shares used in computing basic and diluted net loss per share              | 61,327                              | 56,961     | 59,224                             | 56,365      |
| Comprehensive loss:  |                                     |            |                                    |             |
| Net loss   | \$(5,857                            | ) \$(6,603 | ) \$(29,256                        | ) \$(25,064 |
| Foreign currency translation adjustment                                    | (139                                | ) —        | (32                                | ) —         |
| Comprehensive loss   | \$(5,996                            | ) \$(6,603 | ) \$(29,288                        | ) \$(25,064 |

The accompanying notes are an integral part of these financial statements

Table of Contents

ENDOLOGIX, INC.  
 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS  
 (In thousands)  
 (Unaudited)

|  | Nine Months Ended<br>September 30, |             |
|--|------------------------------------|-------------|
|  | 2012                               | 2011        |
| Cash flows from operating activities:  |                                    |             |
| Net loss   | \$(29,256                          | ) \$(25,064 |
| Adjustments to reconcile net loss to net cash used in operating activities:  |                                    |             |
| Depreciation and amortization  | 1,651                              | 2,244       |
| Stock-based compensation   | 3,522                              | 3,164       |
| Change in fair value of contingent consideration related to acquisition      | 12,700                             | 10,000      |
| Loss on sale of equipment  | —                                  | (141        |
| Changes in operating assets and liabilities:                                 |                                    |             |
| Accounts receivable  | (4,074                             | ) (4,055    |
| Other receivables  | 103                                | 407         |
| Inventories  | (957                               | ) (7,126    |
| Prepaid expenses and other current assets                                    | (582                               | ) (668      |
| Accounts payable   | (1,983                             | ) 699       |
| Accrued payroll  | 407                                | 1,929       |
| Accrued expenses and other current liabilities                               | 1,262                              | 1,058       |
| Settlement cost  | 5,000                              | —           |
| Deferred revenue   | (8                                 | ) —         |
| Net cash used in operating activities  | (12,215                            | ) (17,553   |
| Cash flows from investing activities:  |                                    |             |
| Purchases of property and equipment  | (1,408                             | ) (1,801    |
| Purchases of patent license  | (100                               | ) —         |
| Business acquisition   | (2,367                             | ) —         |
| Net cash used in investing activities  | (3,875                             | ) (1,801    |
| Cash flows from financing activities:  |                                    |             |
| Proceeds from sale of common stock under secondary offering, net of expenses | 40,069                             | —           |
| Proceeds from sale of common stock under employee stock purchase plan        | 1,409                              | 1,053       |
| Proceeds from exercise of stock options                                      | 2,355                              | 4,044       |
| Repayments of long-term debt   | —                                  | (62         |
| Net cash provided by financing activities                                    | 43,833                             | 5,035       |
| Effect of exchange rate changes on cash and cash equivalents                 | (38                                | ) —         |
| Net increase (decrease) in cash and cash equivalents                         | 27,705                             | (14,319     |
| Cash and cash equivalents, beginning of period                               | 20,035                             | 38,191      |
| Cash and cash equivalents, end of period                                     | \$47,740                           | \$23,872    |
| The accompanying notes are an integral part of these financial statements    |                                    |             |

Table of Contents

ENDOLOGIX, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(all tabular amounts presented in thousands, except per share, per unit, and number of years)

(Unaudited)

1. Description of Business, Basis of Presentation, and Operating Segment

(a) Description of Business

Endologix, Inc. (the "Company") is a Delaware corporation with corporate headquarters and production facilities in Irvine, California. The Company develops, manufactures, markets, and sells innovative medical devices for the treatment of aortic disorders. The Company's principal product is a stent graft and delivery system (the "ELG System"), for the treatment of abdominal aortic aneurysms ("AAA") through minimally-invasive endovascular repair ("EVAR"). Sales of the Company's ELG System (including device extensions and accessories) to hospitals and third-party distributors provide the sole source of reported revenue.

The Company's ELG System consists of (i) a self-expanding cobalt chromium alloy stent covered by expanded polytetrafluoroethylene (commonly referred to as "ePTFE") graft material (the "ELG Device") and (ii) an accompanying delivery catheter. Once the ELG Device is fixed in its proper position within the abdominal aorta it provides a conduit for blood flow and relieves pressure within the weakened or "aneurysmal" section of the vessel wall, greatly reducing the potential for the AAA to rupture.

(b) Basis of Presentation

The accompanying Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") and with the rules and regulations of the U.S. Securities and Exchange Commission ("SEC"). These financial statements include the financial position, results of operations, and cash flows of the Company, including its wholly-owned subsidiaries. All inter-company accounts and transactions have been eliminated in consolidation.

The interim financial data as of September 30, 2012, and for the three and nine months ended September 30, 2012, is unaudited and is not necessarily indicative of the results for a full year. In the opinion of the Company's management, the interim data includes normal and recurring adjustments necessary for a fair presentation of the Company's financial results for the three and nine months ended September 30, 2012. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to SEC rules and regulations relating to interim financial statements.

The accompanying Condensed Consolidated Financial Statements should be read in conjunction with the Company's audited Consolidated Financial Statements and Notes thereto included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2011, filed with the SEC on March 6, 2012.

As part of the financial statement preparation process, the Company's management has evaluated whether significant events have occurred after the balance sheet date of September 30, 2012 through October 31, 2012, representing the date this Quarterly Report on Form 10-Q was filed with the SEC, and concluded that no additional disclosures or adjustments were required.

(c) Operating Segment

The Company has one reportable operating segment that is focused exclusively on the development, manufacture, marketing, and sale of ELG Systems for the treatment of aortic disorders. For the nine months ended September 30,

2012, all of the Company's revenue and related expenses were solely attributable to these activities. Substantially all of the Company's long-lived assets are located in the U.S.

## 2. Use of Estimates and Summary of Significant Accounting Policies

The preparation of financial statements in conformity with GAAP requires the Company's management to make estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosure of contingent liabilities. On an on-going basis, the Company's management evaluates its estimates, including those related to (i) collectibility of customer accounts; (ii) whether the cost of inventories can be recovered; (iii) the value assigned to, and estimated useful life of, intangible assets; (iv) realization of tax assets and estimates of tax liabilities; (v) likelihood of payment and value of

Table of Contents

ENDOLOGIX, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(all tabular amounts presented in thousands, except per share, per unit, and number of years)

(Unaudited)

contingent liabilities; and (vi) potential outcome of litigation. Such estimates are based on management's judgment which takes into account historical experience and various assumptions. Nonetheless, actual results may differ from management's estimates.

The following critical accounting policies and estimates were used in the preparation of the accompanying Condensed Consolidated Financial Statements:

## (i) Accounts Receivable

Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is management's best estimate of the amount of probable credit losses in existing accounts receivable. Account balances are charged off against the allowance after appropriate collection efforts are exhausted.

## (ii) Inventories

The Company values inventory at the lower of the actual cost to purchase or manufacture the inventory, or the market value for such inventory. Cost is determined on the first-in, first-out method (FIFO). The Company regularly reviews inventory quantities in process and on hand, and when appropriate, records a provision for obsolete and excess inventory. The provision is based on actual loss experience and a forecast of product demand compared to its remaining shelf life.

## (iii) Property and Equipment

Property and equipment are stated at cost and depreciated on a straight-line basis over the following estimated useful lives:

|  | Useful Life  |
|--|--|
| Office furniture, computer hardware, computer software, and production equipment | Three to eight years   |
| Leasehold improvements   | Shorter of useful life or remaining term of lease (with expected extensions) |

Maintenance and repairs are expensed as incurred, while leasehold improvements are capitalized and amortized over the shorter of their estimated useful lives or the remaining lease term (including expected extensions). Upon sale or disposition of property and equipment, any gain or loss is included in the accompanying Condensed Consolidated Statement of Operations.

## (iv) Goodwill and Intangible Assets

|                                     | Useful Life   |
|-------------------------------------|---|
| Goodwill                            | Indefinite lived  |
| In-process research and development | Indefinite lived until commercial launch of underlying technology, then amortized over its then remaining useful life on a pro-rata basis |
| Developed technology                | Ten years, amortized on a straight-line basis   |
| Patents                             | Five years, amortized on a straight-line basis  |
| Customer list                       | Three years, amortized on a pro-rata basis  |

Goodwill and other intangible assets with indefinite lives are not subject to amortization, but are tested for impairment annually as of June 30, or whenever events or changes in circumstances indicate that the asset might be impaired.

The Company evaluates the possible impairment of its long-lived assets, including finite lived intangible assets, (i) if/when events or changes in circumstances occur that indicate that the carrying value of assets may not be recoverable (there were no such events at September 30, 2012, and through the date this Quarterly Report on Form 10-Q was filed with the SEC); or (ii) in the case of indefinite lived intangible assets, at each annual impairment assessment date.

For purposes of impairment testing, the Company's entire ELG Systems business represents the lowest level of separately identifiable cash flows. The impairment evaluation utilizes the Company's ten-year operating plan (updated annually) in determining the undiscounted cash flows expected to be generated by its ELG Systems business through continuing operations. Such undiscounted cash flows are next compared to the carrying amount of the asset or asset group to determine if there is an indication of impairment.

7

---

Table of Contents

ENDOLOGIX, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(all tabular amounts presented in thousands, except per share, per unit, and number of years)

(Unaudited)

The undiscounted net cash flows expected to be generated by the ELG Systems business exceeded its carrying amount as of June 30, 2012; therefore, this asset group is not considered to be impaired. Such conclusion is based upon management's significant judgments and estimates inherent in the Company's ten-year operating plan, including assumptions pertaining to revenue growth, expense trends, and working capital management. Accordingly, changes in the Company's business circumstances could adversely impact the future results of its assessment of long-lived asset impairment.

(v) Fair Value Measurements

The Company applies relevant GAAP in measuring the fair value of its Contingent Payment (see Note 9), and assigning fair value of assets acquired and liabilities assumed as part of its business combination accounting (see Note 12). Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. GAAP establishes a fair value hierarchy that distinguishes between (i) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (ii) an entity's own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:

Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

Level 3 - Inputs that are both significant to the fair value measurement and unobservable.

(vi) Contingent Consideration for Business Acquisition

The Company's management determined the fair value of contingently issuable common stock on the Nellix acquisition date (see Note 9) using a probability-based income approach with an appropriate discount rate (determined using both Level 1 and Level 3 inputs). Changes in the fair value of this contingently issuable common stock are determined at each period end and are recorded in the other income/(expense) section of the accompanying Condensed Consolidated Statements of Operations, and the non-current liabilities section of the accompanying Condensed Consolidated Balance Sheet.

(vii) Fair Value of Financial Instruments

The carrying amount of the Company's financial instruments (consisting entirely of money market funds) included in cash and cash equivalents in the accompanying Condensed Consolidated Balance Sheets approximates fair value (utilizing Level 1 inputs) because of their ability to immediately convert to cash with minimal change in value.

(viii) Revenue Recognition

The Company recognizes revenue when all of the following criteria are met:

- Appropriate evidence of a binding arrangement exists with the customer;
- The sales price for the ELG System (including device extensions and accessories) is established with the customer;

• The ELG System has been used in an EVAR procedure, or the distributor has assumed title; and

- Collection of the corresponding receivable is reasonably assured at the time of sale.

For sales made to hospitals, the Company recognizes revenue upon completion of an EVAR procedure, when the ELG Device is implanted in a patient. For sales made to distributors, the Company recognizes revenue when title passes, which is typically at the time of shipment, as this represents the period that the customer has assumed custody of the ELG System, without right of return, and assumed risk of loss.

The Company does not offer rights of return and has no post-delivery obligations, other than honoring a standard warranty.

Table of Contents

ENDOLOGIX, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(all tabular amounts presented in thousands, except per share, per unit, and number of years)

(Unaudited)

(ix) Shipping Costs

Shipping costs billed to customers are reported within revenue, with the corresponding costs reported within costs of goods sold.

(x) Foreign Currency Transactions

The assets and liabilities of the Company's foreign subsidiaries are translated at the rates of exchange at the balance sheet date. The income and expense items of these subsidiaries are translated at average monthly rates of exchange. Gains and losses resulting from foreign currency transactions, which are denominated in a currency other than the respective entity's functional currency are included in other income (expense), net, within the accompanying Condensed Consolidated Statement of Operations. Foreign currency translation adjustments between the respective entity's functional currency and the U.S. dollar are recorded to accumulated other comprehensive loss within the stockholders' equity section of the accompanying Condensed Consolidated Balance Sheets.

(xi) Income Taxes

The Company records the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts reported in the financial statements, as well as operating losses and tax credit carry forwards. The Company has recorded a full valuation allowance to reduce its net deferred tax assets to zero, because the Company believes that, based upon a number of factors, it is more likely than not that the deferred tax assets will not be realized. If the Company were to determine that it would be able to realize its deferred tax assets in the future, an adjustment to the valuation allowance on its deferred tax assets would increase net income in the period such determination was made.

(xii) Net Income (Loss) Per Share

Net income (loss) per common share is computed using the weighted average number of common shares outstanding during the periods presented. Because of the net losses during the three and nine months ended September 30, 2012 and 2011, options to purchase the common stock, restricted stock awards, and restricted stock units of the Company were excluded from the computation of net loss per share for these periods because the effect would have been antidilutive.

(xiii) Research and Development Costs

Research and development costs are expensed as incurred.

(xiv) Product Warranty

Within six months of shipment, certain customers may request replacement of products they receive that do not meet product specifications; no other warranties are offered. The Company contractually disclaims responsibility for any damages associated with physician's use of its ELG System. Historically, the Company has not experienced a significant amount of costs associated with its warranty policy.

### 3. Stock-Based Compensation

#### Stock Options and Restricted Stock

The Company values stock-based awards, including stock options and restricted stock, as of the date of grant. The Company uses the Black-Scholes option-pricing model in valuing granted stock options. The fair value per share of granted restricted stock is equal to the Company's closing stock price on the date of grant.

The Company recognizes stock-based compensation expense (net of estimated forfeitures) using the straight-line method over the requisite or implicit service period, as applicable. Forfeitures are estimated at the time of grant and the forfeiture assumption is periodically adjusted for actual activity.

#### Employee Stock Purchase Plan

Under the terms of the Company's 2006 Employee Stock Purchase Plan (the "ESPP"), eligible employees can purchase common stock through payroll deductions. The purchase price is equal to the closing price of the Company's common stock on

Table of Contents

ENDOLOGIX, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(all tabular amounts presented in thousands, except per share, per unit, and number of years)

(Unaudited)

the first or last day of the offering period (whichever is less) minus a 15% discount. The Company uses the Black-Scholes option-pricing model, in combination with the discounted employee price, in determining the value of ESPP expense to be recognized during each offering period.

## Stock-Based Compensation Expense Summary

The Company classified related compensation expense in the accompanying Condensed Consolidated Statement of Operations, based on the Company department to which the recipient belongs. Stock-based compensation expense included in cost of goods sold and operating expenses during the three and nine months ended September 30, 2012 and 2011, was as follows:

|                                 | Three Months Ended |          | Nine Months Ended |          |
|---------------------------------|--------------------|----------|-------------------|----------|
|                                 | September 30,      |          | September 30,     |          |
|                                 | 2012               | 2011     | 2012              | 2011     |
| Cost of goods sold              | \$ 183             | \$ 141   | \$ 387            | \$ 181   |
| Operating expenses:             |                    |          |                   |          |
| Research and development        | 165                | 238      | 498               | 653      |
| Clinical and regulatory affairs | 67                 | 37       | 145               | 98       |
| Marketing and sales             | 361                | 269      | 1,041             | 1,120    |
| General and administrative      | 389                | 595      | 1,451             | 1,112    |
| Total operating expenses        | \$ 982             | \$ 1,139 | \$ 3,135          | \$ 2,983 |
| Total                           | \$ 1,165           | \$ 1,280 | \$ 3,522          | \$ 3,164 |

## 4. Net Loss Per Share

Net loss per share was computed by dividing net loss by the weighted average number of common shares outstanding for the three and nine months ended September 30, 2012 and 2011 as follows:

|  | Three Months Ended |             | Nine Months Ended |              |   |
|--|--------------------|-------------|-------------------|--------------|---|
|  | September 30,      |             | September 30,     |              |   |
|  | 2012               | 2011        | 2012              | 2011         |   |
| Net loss                               | \$ (5,857          | ) \$ (6,603 | ) \$ (29,256      | ) \$ (25,064 | ) |
| Weighted average shares                | 61,327             | 56,961      | 59,224            | 56,365       |   |
| Net loss per share - basic and diluted | \$ (0.10           | ) \$ (0.12  | ) \$ (0.49        | ) \$ (0.44   | ) |

The following outstanding Company securities were excluded from the above calculations of net loss per share because their impact would have been anti-dilutive due to the net losses during the three and nine months ended September 30, 2012 and 2011:

|                         | Three Months Ended |      | Nine Months Ended |      |
|-------------------------|--------------------|------|-------------------|------|
|                         | September 30,      |      | September 30,     |      |
|                         | 2012               | 2011 | 2012              | 2011 |
| Common stock options    | 3,484              | 13   | 3,679             | 429  |
| Restricted stock awards | 487                | 640  | 487               | 640  |

Edgar Filing: ENDOLOGIX INC /DE/ - Form 10-Q

|                        |       |     |       |       |
|------------------------|-------|-----|-------|-------|
| Restricted stock units | 419   | —   | 419   | —     |
| Total                  | 4,390 | 653 | 4,585 | 1,069 |

5. Balance Sheet Account Detail

10

---

Table of Contents

ENDOLOGIX, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(all tabular amounts presented in thousands, except per share, per unit, and number of years)

(Unaudited)

## (a) Inventories

Inventories are stated at the lower of cost or market value. Inventories consisted of the following:

|                 | September 30,<br>2012 | December 31,<br>2011 |
|-----------------|-----------------------|----------------------|
| Raw materials   | \$4,741               | \$3,260              |
| Work-in-process | 5,182                 | 4,617                |
| Finished goods  | 9,138                 | 10,222               |
| Inventories     | \$19,061              | \$18,099             |

## (b) Goodwill and Intangible Assets

The following table presents goodwill, indefinite lived intangible assets, finite lived intangible assets, and related accumulated amortization:

|   | September 30,<br>2012 | December 31,<br>2011 |
|---|-----------------------|----------------------|
| Goodwill                                    | \$28,969              | \$27,073             |
| Intangible assets:                          |                       |                      |
| Indefinite lived intangibles                |                       |                      |
| In-process research and development (a)     | \$40,100              | \$40,100             |
| Trademarks and trade names                  | 2,708                 | 2,708                |
| Total indefinite lived intangibles          | \$42,808              | \$42,808             |
| Finite lived intangibles                    |                       |                      |
| Developed technology                        | \$—                   | \$14,050             |
| Accumulated amortization                    | —                     | (13,465)             |
| Developed technology, net                   | \$—                   | \$585                |
| Patent                                      | \$200                 | \$100                |
| Accumulated amortization                    | (75)                  | (54)                 |
| Patent, net                                 | \$125                 | \$46                 |
| Customer list                               | \$508                 | \$—                  |
| Accumulated amortization                    | (42)                  | —                    |
| Customer list, net                          | \$466                 | \$—                  |
| Intangible assets (excluding goodwill), net | \$43,399              | \$43,439             |

(a) Will be reclassified to finite lived intangibles and amortized upon the commercial launch of the product (Nellix Device) associated with this intangible asset.

Goodwill and other intangible assets with indefinite lives are not subject to amortization, but are tested for impairment annually or whenever events or changes in circumstances indicate that the asset might be impaired. The Company most recently performed its annual goodwill and other indefinite lived intangible asset impairment analysis as of June 30, 2012, with

Table of Contents

ENDOLOGIX, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(all tabular amounts presented in thousands, except per share, per unit, and number of years)

(Unaudited)

no resulting impairment. The Company will continue to test for impairment as of June 30 each year, or whenever events or changes in circumstances indicate that an asset might be impaired.

Intangible assets with finite lives are amortized over their expected useful life and related impairment testing is only performed when impairment indicators are present.

The Company recognized amortization expense on intangible assets during the three and nine months ended September 30, 2012 and 2011 as follows:

|                      | Three Months Ended |       | Nine Months Ended |         |
|----------------------|--------------------|-------|-------------------|---------|
|                      | September 30,      |       | September 30,     |         |
|                      | 2012               | 2011  | 2012              | 2011    |
| Amortization expense | \$52               | \$356 | \$648             | \$1,069 |

Estimated amortization expense for the remainder of 2012 and the three succeeding fiscal years (which includes estimated amortization of intangible assets to commence with the expected commercial launch of the Nellix Device in Europe during the second half of 2013) is as follows:

|                      | Amortization<br>Expense |
|----------------------|-------------------------|
| Remainder of 2012    | \$54                    |
| 2013                 | 268                     |
| 2014                 | 392                     |
| 2015 and thereafter  | 39,977                  |
| 6. Credit Facilities |                         |

In October 2009, the Company entered into a revolving credit facility with Wells Fargo Bank (“Wells”), which was last amended on October 9, 2012, whereby the Company may borrow up to \$20.0 million, subject to the calculation and limitation of a borrowing base (the “Wells Credit Facility”). All amounts owing under the Wells Credit Facility will become due and payable upon its expiration on March 31, 2013. As of September 30, 2012, the Company did not have any outstanding borrowings under the Wells Credit Facility. Any outstanding amounts under the Wells Credit Facility bear interest at a variable rate equal to the Wells prime rate, plus 1.00%, which is payable on a monthly basis. The Wells Credit Facility carried a 0.2% unused commitment fee through May 19, 2012, when this fee was eliminated. The Wells Credit Facility is collateralized by all of the Company's assets, except its intellectual property.

The Wells Credit Facility contains financial covenants requiring the Company to (i) maintain a minimum current ratio of 1.5, equal to the quotient of modified current assets to current liabilities, as defined in the Wells Credit Facility (the "Current Ratio Covenant"), and (ii) not exceed operating loss amounts (excluding non-cash contingent consideration associated with the acquisition of Nellix) of \$6.5 million for the quarter ended March 31, 2012; \$11.0 million for the six months ended June 30, 2012; \$13.0 million for the nine months ended September 30, 2012; and \$13.0 million for the year ended December 31, 2012 (the "Operating Loss Covenant"). The Wells Credit Facility also includes a negative covenant limiting 2012 capital expenditures to an aggregate \$3.0 million.

The Company was not in compliance with the Operating Loss Covenant for the nine months ended September 30, 2012. The Company obtained a waiver for the breach of the Operating Loss Covenant from Wells on October 26, 2012, whereby Wells agreed to forbear from enforcing their default rights under the Wells Credit Facility. The waiver does not apply to any subsequent breaches of the same provision, nor any breach of any other provision specified

within the Wells Credit Facility.

The Wells Credit Facility also contains a “material adverse change” clause (“MAC”). If the Company encounters difficulties that would qualify as a MAC in its (i) operations, (ii) condition (financial or otherwise), or (iii) ability to repay amounts outstanding under the Wells Credit Facility, it could be canceled at Wells' sole discretion. Wells could then elect to declare the indebtedness, together with accrued interest and other fees, to be immediately due and payable and proceed against any collateral securing such indebtedness.

12

---

Table of Contents

ENDOLOGIX, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(all tabular amounts presented in thousands, except per share, per unit, and number of years)

(Unaudited)

## 7. Revenue by Geographic Region

The Company's revenue by geographic region, was as follows:

|                        | Three Months Ended |          | Nine Months Ended |          |
|------------------------|--------------------|----------|-------------------|----------|
|                        | September 30,      |          | September 30,     |          |
|                        | 2012               | 2011     | 2012              | 2011     |
| United States          | \$21,289           | \$20,320 | \$63,695          | \$52,280 |
| Europe:                |                    |          |                   |          |
| Direct                 | \$1,692            | \$—      | \$4,071           | \$—      |
| Distributor            | 431                | 640      | 1,612             | 2,703    |
| Total Europe           | \$2,123            | \$640    | \$5,683           | \$2,703  |
| Rest of World ("ROW"): |                    |          |                   |          |
| Latin America          | \$1,670            | \$354    | \$3,785           | \$3,190  |
| Asia/Pacific           | 1,614              | 988      | 3,562             | 1,852    |
| Total ROW              | \$3,284            | \$1,342  | \$7,347           | \$5,042  |
| Revenue                | \$26,696           | \$22,302 | \$76,725          | \$60,025 |

U.S. The Company's U.S. sales were solely derived from its sales force, divided among twelve geographic sales regions.

Europe. For the three and nine months ended September 30, 2012, the Company's European sales were derived from (i) its direct European sales force (including dedicated sales agents), serving much of Western Europe, and (ii) five independent distributors serving the markets in Italy (through June 2012), Greece, Turkey, Poland, and Ireland. For the three and nine months ended September 30, 2011, the Company's European sales were derived solely from these independent distributors.

ROW. The Company's ROW sales were solely derived from independent distributors.

## 8. Commitments and Contingencies

## (a) Leases

The Company leases its administrative, research, and manufacturing facilities in Irvine, California, and certain equipment, under long-term agreements that are accounted for as operating leases. The facility lease agreements require the Company to pay operating costs, including property taxes, insurance, and maintenance.

Future minimum payments by year under non-cancelable leases with initial terms in excess of one year were as follows as of September 30, 2012:

|                |       |
|----------------|-------|
| Remaining 2012 | \$143 |
|----------------|-------|

|                     |         |
|---------------------|---------|
| 2013                | 656     |
| 2014                | 474     |
| 2015 and thereafter | —       |
|                     | \$1,273 |

(b) Employment Agreements and Retention Plan

13

---

Table of Contents

ENDOLOGIX, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(all tabular amounts presented in thousands, except per share, per unit, and number of years)

(Unaudited)

The Company has entered into employment agreements with its officers and certain other “key employees” under which payment and benefits would become payable in the event of termination by the Company for any reason other than cause, upon a change in control of the Company, or by the employee for good reason. The payment will generally be equal to six months of the employee’s then current salary for termination by the Company without cause, and generally be equal to twelve months of salary if upon a change in control of the Company.

(c) Legal Matters

The Company from time to time is involved in various claims and legal proceedings of a nature considered normal and incidental to its business. These matters may include product liability, intellectual property, employment, and other general claims. The Company accrues for contingent liabilities when it is probable that a liability has been incurred and the amount can be reasonably estimated. The accruals are adjusted periodically as assessments change or as additional information becomes available.

The Company had been involved in litigation with Cook Incorporated (“Cook”). Cook alleged that the Company infringed two of its patents, granted in 1991 and 1998, which expired on October 17, 2009 and October 25, 2011, respectively (the “Patent Dispute”). The lawsuit was filed by Cook in the U.S. District Court for the Southern District of Indiana (the “Court”), on October 8, 2009.

On October 16, 2012, the Company entered into a settlement agreement with Cook for the Patent Dispute (the “Settlement Agreement”), which included a full release from liability for all asserted claims. Without admitting any liability, the Company agreed to make a one-time cash payment to Cook of \$5.0 million, which is expected to occur in November 2012.

The Company's accrual for the \$5.0 million Settlement Agreement is presented in the accompanying Condensed Consolidated Statements of Operations within operating expenses as settlement costs for the three and nine months ended September 30, 2012.

9. Contingently Issuable Common Stock

On December 10, 2010 (the “Nellix Closing Date”), the Company completed its acquisition of Nellix, Inc., a pre-revenue, AAA medical device company. The purchase price consisted of 3.2 million of the Company's common shares, issuable to the former Nellix stockholders as of the Nellix Closing Date, then representing a value of \$19.4 million. Additional payments, solely in the form of the Company's common shares (the “Contingent Payment”), will be made upon the achievement of a revenue milestone and a regulatory approval milestone (collectively, the “Nellix Milestones”).

The ultimate value of the Contingent Payment will be determined on the date that each Nellix Milestone is achieved. The number of issuable shares will be established using an applicable per share price, which is subject to a ceiling and/or floor, resulting in a maximum of 10.2 million shares issuable upon the achievement of the Nellix Milestones. As of the Closing Date, the fair value of the Contingent Payment was estimated to be \$28.2 million. At September 30, 2012, the Company's stock price closed at \$13.82 per share. Thus, had the Nellix Milestones been achieved on September 30, 2012, the Contingent Payment would have comprised 4.2 million shares, representing a value of \$58.0 million.

The value of the Contingent Payment is derived using a discounted income approach model, with a range of probabilities and assumptions related to the timing and likelihood of achievement of the Nellix Milestones (which include Level 3 inputs - see Note 2(v) and the Company's stock price (Level 1 input) as of the balance sheet date. These varying probabilities and assumptions and changes in the Company's stock price have required fair value adjustments of the Contingent Payment in periods subsequent to the Nellix Closing Date.

The per share price of the Company's common stock increased by \$2.34, or 20%, between December 31, 2011 and September 30, 2012. The increase in the value of the Company's common stock was the primary driver affecting the increase in the fair value of the Contingent Payment during the nine months ended September 30, 2012.

The Contingent Payment fair value will continue to be evaluated on a quarterly basis until milestone achievement occurs, or until the expiration of the "earn-out period," as defined within the Nellix purchase agreement. Adjustments to the fair value of the Contingent Payment are recognized within other income (expense) in the Condensed Consolidated Statements of Operations.

Table of Contents

ENDOLOGIX, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(all tabular amounts presented in thousands, except per share, per unit, and number of years)

(Unaudited)

|  | Fair Value of Contingently<br>Issuable Common Stock |
|--|---|
| December 31, 2011  | \$38,700  |
| Fair value adjustment of Contingent Payment for nine months ended September 30, 2012 | 12,700  |
| September 30, 2012   | \$51,400  |

## 10. Income Tax Expense

The Company applied an estimated annual effective tax rate (“ETR”) approach for calculating a tax provision for interim periods, as required under GAAP. The Company recorded a (benefit) provision for income taxes of \$(0.2) million and \$0.3 million for the three and nine ended September 30, 2012, respectively representing an ETR of (2.5)% and 1.0%, respectively. The Company's ETR for the three and nine months ended September 30, 2012 differs from the U.S. federal statutory tax rate of 35% primarily as a result of nondeductible expenses (including the Nellix Contingent Payment), state income taxes, foreign income taxes, and the impact of a full valuation allowance of its deferred tax assets.

The Company has evaluated the available evidence supporting the realization of its deferred tax assets, including the amount and timing of future taxable income, and has determined that it is more likely than not that its net deferred tax assets will not be realized. Due to uncertainties surrounding the realization of the deferred tax assets, the Company maintains a full valuation allowance against all deferred tax assets. If/when the Company determines that it will be able to realize some portion or all of its deferred tax assets, an adjustment to its valuation allowance on its deferred tax assets would have the effect of increasing net income in the period(s) such determination is made.

## 11. June 2012 Stock Sale

On May 30, 2012, the Company executed a common stock purchase agreement (the "Stock Purchase Agreement") with Piper Jaffray & Co. ("Piper"). As part of the Stock Purchase Agreement (pursuant to a shelf registration statement filed with the SEC on May 30, 2012, which became effective immediately upon filing), Piper purchased 2.7 million shares of the Company's common stock at \$13.00 per share on June 5, 2012, and subsequently executed an option to purchase an additional 0.4 million shares at \$13.00 per share, which closed on June 7, 2012.

These two transactions resulted in gross proceeds to the Company of \$40.3 million (net of \$0.1 million withheld by Piper to cover their applicable legal fees). The Company's direct costs to complete this transaction, substantially consisting of legal fees and accounting fees, totaled \$0.2 million and are reflected as a reduction of additional paid-in capital in the accompanying Condensed Consolidated Balance Sheets as of September 30, 2012, in accordance with applicable GAAP.

## 12. Business Combination

## GVT Acquisition Overview

On July 2, 2012 (the “GVT Closing Date”), the Company terminated its exclusive distribution agreement with its Italian distributor, Global Vascular Technologies S.r.l. ("GVT"), in order to begin direct sales activity in Italy. Immediately after termination, the Company closed an asset purchase agreement for the underlying Italian distribution

business from GVT for total consideration of \$2.4 million (the “GVT Acquisition”). This business consists of (i) a trained and assembled sales workforce (on the GVT Closing Date, four former GVT sales employees joined the Company to assume similar roles), and (ii) various active distribution and direct sales agreements, which were assumed by the Company.

Since July 2, 2012, the results of operations of the GVT business, since renamed Endologix Italia S.r.l., have been included in the accompanying Condensed Consolidated Statements of Operations.

#### Direct Costs of the GVT Acquisition

The Company's direct costs of the GVT Acquisition included legal and accounting fees of \$0.4 million. Such amount is included in contract termination and business acquisition expenses within the accompanying Condensed Consolidated Statements of Operations for the nine months ended September 30, 2012.

Table of Contents

ENDOLOGIX, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(all tabular amounts presented in thousands, except per share, per unit, and number of years)

(Unaudited)

## GVT Purchase Price Allocation

The GVT purchase price of \$2.4 million was allocated based on the preliminary fair value estimates of the acquired assets and liabilities (the Company expects to finalize the GVT purchase price allocation by December 31, 2012, upon completion of the valuation), and is as follows:

|  |         |
|--|---------|
| Identifiable intangible assets (customer list) | \$ 500  |
| Total identifiable net assets                  | 500     |
| Goodwill                                       | 1,867   |
| Total purchase price allocation                | \$2,367 |

Identified intangible assets associated with the acquisition of GVT (customer list) will be amortized to general and administrative expense over the estimated period of benefit of three years. To estimate fair value of the customer list, the Company used the “income approach” which is a valuation technique that converts future expected net cash flows to be derived from this asset into a single, present-valued amount.

## Goodwill

Goodwill presented above of \$1.9 million represents the difference of the GVT purchase price of \$2.4 million minus the net identifiable intangible asset acquired.

Applicable GAAP requires that the value of a trained and assembled workforce be included in goodwill, and not presented as a separate intangible asset. The four sales employees hired as part of the GVT Acquisition are clinically adept with the Company's ELG System; have long-standing professional relationships with Italian distributors and physicians; and have a high degree of sales experience within the Italian EVAR market. The Company believes these acquired employees will provide the foundation for meaningful revenue growth in Italy, which is widely recognized as the second-largest EVAR market in Europe.

In accordance with applicable GAAP, the Company will not amortize goodwill associated with the GVT acquisition. Goodwill is subject to annual impairment testing. The goodwill resulting from the GVT acquisition is expected to be amortized over 18 years for tax purposes.

## Pro Forma Financial Information

The following unaudited pro forma financial information is presented to reflect the results of the Company's consolidated operations for the three and nine months ended September 30, 2012 and 2011, as if the acquisition of GVT had occurred on January 1, 2011. Adjustments have been made to (i) revenue for estimates of increased sales prices, had the sales been made directly to our former distributor's customers; (ii) operating expenses for increased payroll costs related to four additional sales employees; and (iii) operating expense decreases for the exclusion of one-time transactions costs directly associated with the GVT Acquisition. These pro forma results have been prepared for general comparative purposes only and may not be indicative of what operating results would have been, had the acquisition actually taken place on January 1, 2011, and may not be indicative of future operating results.



Table of Contents

ENDOLOGIX, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

(all tabular amounts presented in thousands, except per share, per unit, and number of years)

(Unaudited)

|  | (Pro Forma)                      |           |   |
|--|----------------------------------|-----------|---|
|  | Three Months Ended September 30, |           |   |
|  | 2012                             | 2011      |   |
| Revenue                                | \$26,696                         | \$22,378  |   |
| Cost of goods sold                     | 6,444                            | 4,829     |   |
| Total operating expenses               | 27,185                           | 22,770    |   |
| Net loss                               | (5,857                           | ) (6,676  | ) |
| Net loss per share - basic and diluted | (0.10                            | ) (0.12   | ) |
|  | (Pro Forma)                      |           |   |
|  | Nine Months Ended September 30,  |           |   |
|  | 2012                             | 2011      |   |
| Revenue                                | \$76,910                         | \$60,346  |   |
| Cost of goods sold                     | 18,148                           | 13,352    |   |
| Total operating expenses               | 74,647                           | 62,271    |   |
| Net loss                               | (28,947                          | ) (25,190 | ) |
| Net loss per share - basic and diluted | (0.49                            | ) (0.45   | ) |

## 13. Subsequent Event

The Company settled patent litigation with Cook Incorporated for \$5.0 million on October 16, 2012. See Note 8(c) for further discussion.

Table of Contents

Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Cautionary Note Regarding Forward-Looking Statements

In addition to the historical financial information included herein, this Quarterly Report on Form 10-Q includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), that are based on management's reasonable beliefs, as well as on assumptions made by and information currently available to management. All statements other than statements of historical fact included in this Quarterly Report on Form 10-Q, including, without limitation, statements under "Management's Discussion and Analysis of Financial Condition and Results of Operations" and statements located elsewhere herein regarding our financial position and business strategy, may constitute forward-looking statements. You generally can identify forward-looking statements by the use of forward-looking terminology such as "believes," "may," "will," "expects," "intends," "estimates," "anticipates," "plans," "seek," "continues," or the negative thereof or variations thereon or similar terminology, although not all forward-looking statements contain these words. Such forward-looking statements involve known and unknown risks, including, but not limited to, market acceptance of our products, general economic and business conditions, the regulatory environment in which we operate, the level and availability of third party payor medical reimbursements, competitive activities, protection of intellectual property rights or other risks. Our actual results, performance or achievements may differ materially from any future results, performance or achievements expressed or implied from such forward-looking statements. Important factors that could cause our actual results, performance or achievements to differ materially from our expectations are disclosed in our Annual Report on Form 10-K for the year ended December 31, 2011, filed with the SEC on March 6, 2012, including but not limited to those factors discussed in "Management's Discussion and Analysis of Financial Condition and Results of Operations," "Risk Factors," "Consolidated Financial Statements" and "Notes to Consolidated Financial Statements." All subsequent written and oral forward-looking statements attributable to us or by persons acting on our behalf are expressly qualified in their entirety by these cautionary statements. We expressly disclaim any intent or obligation to update information contained in any forward-looking statement after the date thereof to conform such information to actual results or to changes in our opinions or expectations.

Overview and Outlook

Our Business

Our corporate headquarters and manufacturing facility is located in Irvine, California. We develop, manufacture, market and sell innovative medical devices for the treatment of aortic disorders. Our principal product is a stent graft and delivery catheter for the treatment of abdominal aortic aneurysms ("AAA") through minimally-invasive endovascular repair.

We sell our products through our U.S. and European sales force. In certain European countries, and in other parts of the world, we sell our products through third-party distributors.

We have continued to execute our mission in 2012 of being the leading innovator of medical devices for the treatment of aortic disorders, by:

- Focusing exclusively on the aorta for the commercialization of innovative medical devices.
- Designing and manufacturing devices that are easy to use and result in excellent clinical outcomes.
- Providing excellent clinical and technical support to physicians through an experienced and knowledgeable sales and marketing organization.

Our Products

Our ELG System

Our ELG System consists of our ELG Device (stent graft) and catheter delivery system, branded under the names Powerlink, AFX, IntuiTrak, Peek, and Visiflex. We believe that our ELG System has the following advantages over our competitors:

-

Anatomical Fixation. Our ELG Device is unique in that it sits on the patient's natural aortoiliac bifurcation. This provides a solid foundation for the long-term stability of the device. Alternative ELG devices rely on hooks, barbs and radial force to anchor into the aorta (generally referred to as "proximal fixation") near the renal arteries. We believe anatomical fixation inhibits migration due to the inherent foundational support from the patient's anatomy, as opposed to proximal fixation.

Fully Supported. The main body and limbs of our ELG Device are fully supported by a cobalt chromium alloy stent. The cobalt chromium alloy stent greatly reduces the risk of kinking of the device, even in

## Table of Contents

• tortuous anatomies, eliminating the need for additional procedures or costly peripheral stents. Kinking may result in reduced blood flow and limb thrombosis.

• Unique, Minimally Invasive Delivery System. In the majority of procedures, our ELG System requires only a small surgical incision in one leg. The other leg needs only percutaneous placement of an introducer sheath, three millimeters in diameter. Our competitors' ELG systems typically require surgical exposure of the femoral artery in both legs to introduce the multiple components.

• Preserves Aortic Bifurcation. Our ELG Device allows for future endovascular procedures when continued access across the aortic bifurcation is required. Approximately 30% of AAA patients also have peripheral arterial disease ("PAD"). The preferred endovascular approach to treat a patient with PAD is to access from one side of the groin and to cross over the aortic bifurcation to treat the lesion on the other side. Our ELG Device is the only device presently available that preserves the physician's ability to go back over the aortic bifurcation for future interventions. This is a meaningful feature of our ELG System, as many AAA patients are living longer and having more procedures for PAD.

• Our ELG Device Extensions and Accessories

• Aortic Extensions and Limb Extensions. We offer proximal aortic extensions and limb extensions which attach to the "main body" of our ELG Device, allowing physicians to customize it to fit the patient's anatomy.

• Accessories. We offer various accessories to facilitate the optimal delivery of our ELG Device, including compatible guidewires, snares, and catheter introducer sheaths.

• Our Product Evolution

• Our core product line has evolved considerably over the years, as highlighted below.

• Powerlink Infrarenal Bifurcated Systems ("Powerlink"). Powerlink is our original ELG System and was commercialized in Europe in 1999 and in the U.S. in 2004. We have since branded the delivery systems for Powerlink under the names Peek, Visiflex, IntuiTrak, and AFX.

• Peek. Peek was the name of our original ELG Device delivery system. This system was replaced in all markets (except Japan), first by Visiflex, and subsequently by IntuiTrak.

• IntuiTrak. In October 2008, we received Food and Drug Administration ("FDA") approval for IntuiTrak, which had an improved catheter delivery system to deliver and deploy our ELG Device.

• IntuiTrak Express. In March 2009, we received FDA approval for a delivery system to deliver our 34mm diameter ELG Device extensions.

• AFX. In June 2011, we received FDA approval for our AFX Endovascular AAA System ("AFX"), which we believe provides physicians with improved vascular access and enhanced sealing characteristics of our ELG Device. We began a full commercial launch of AFX in the U.S. in August 2011. AFX subsequently replaced IntuiTrak in the U.S., Brazil, Argentina, and in most of Europe. We expect AFX to be commercialized in other international markets during late 2012 and 2013.

• Recent Clinical Trials and Product Developments

• We believe that our ability to develop new technologies is a key to our future growth and success. Our research and development activities have focused on technology that makes our existing products easier for physicians to use, allows physicians to treat a wider range of AAA patients, and addresses multiple types of aortic disorders.

• Historically, we have focused on developing our ELG Systems to treat infrarenal AAA. However, we expect to devote more resources in the future to develop new technologies to treat more complex anatomies, including juxtarenal aneurysms and diseases of the thoracic aorta.

• PEVAR

• Vascular access for endovascular repair ("EVAR") requires femoral artery exposure (commonly referred to as surgical "cut-down") of one or both femoral arteries, allowing for introduction of ELG systems. Complications from femoral artery exposure is an inherent risk of current EVAR practice. Percutaneous EVAR ("PEVAR") procedures do not require an open surgical cut-down of either femoral artery, as access to the femoral artery is achieved via needle-puncture of the skin (i.e., a percutaneous approach). Based upon peer reviewed literature, advantages to the patient and to the health care system of an



Table of Contents

entirely percutaneous EVAR procedure are reduced surgical procedure times, less post-operative pain, and fewer wound complications.

In 2010, we initiated a PEVAR pivotal clinical trial. The first PEVAR patient was treated at Oklahoma Heart Hospital in April 2010. In February 2012, we completed our clinical trial enrollment at 20 U.S. sites. Patients in this clinical trial were treated with our IntuiTrak system. The clinical trial utilized a "pre-close" technique, facilitated by the Abbott Vascular, Inc. Prostar® XL Percutaneous Vascular Surgical System or Perclose ProGlide® Suture-Mediated Closure System. We have submitted our clinical results to the FDA. We believe that we will receive FDA approval for percutaneous delivery of AFX by the end of 2012.

Xpand

The Xpand Stent Graft ("Xpand") is an ePTFE covered balloon expandable stent graft used in conjunction with Ventana (defined below) to treat patients with short aortic necks (< 15 millimeters), either juxtarenal abdominal aortic aneurysms ("JAA") or pararenal abdominal aortic aneurysms ("PAA").

Ventana

It is estimated that 20% to 30% of diagnosed AAAs are not treatable with currently-approved ELG devices, due to the aneurysm's proximal location to the renal arteries. This includes JAA and PAA patents, as well as patients with short aortic necks (< 15 millimeters). The Ventana Fenestrated Stent Graft System ("Ventana") potentially provides these patients with a less-invasive alternative to open surgical repair, and a life-saving alternative for patients unsuitable for surgery.

In January 2012, we received Investigational Device Exemption ("IDE") approval from the FDA to begin a U.S. clinical trial to evaluate Ventana for the treatment of patients with JAA and PAA and short aortic necks.

In February 2012, we enrolled the first patient in our U.S. clinical trial to evaluate Ventana. Ventana is designed to be used with AFX and Xpand. Though AFX is commercially available in the U.S., Brazil, Argentina, and much of Europe, Ventana and Xpand are not approved for marketing in the U.S. or abroad, and are restricted to investigational use only. Depending upon the clinical trial enrollment and clinical results, we believe we will receive FDA premarket approval for Ventana in 2015, and CE Mark approval by the end of 2012.

Nellix

On December 10, 2010, we completed our acquisition of Nellix (see Note 9 to the accompanying Condensed Consolidated Financial Statements). Using the technology we acquired in this acquisition, we are developing a next generation device- the Nellix EndoVascular Aneurysm Sealing System (the "Nellix Device") to treat infrarenal AAA. The Nellix Device is not approved for marketing in the U.S. or abroad and is presently restricted to international investigational use.

We received CE Mark approval of our current version of the Nellix Device on September 6, 2012. However, we are completing some design and process enhancements before we commercially launch the Nellix Device. We believe we will receive CE Mark approval for the enhanced version of the Nellix Device in the first half of 2013, upon which we will commence our limited market introduction in Europe. We also expect to file our IDE with the FDA in the first half of 2013, after we complete these design and process enhancements.

We believe that the Nellix Device represents groundbreaking technology for endovascular repair of AAA. Anticipated advantages of the Nellix Device include: (i) a low profile delivery system (17 french outer diameter), which is beneficial for patients with small access vessels; (ii) improved ELG device fixation; (iii) simple and intuitive procedure steps; (iv) reduced procedure time; (v) low expected reintervention rate; and (vi) the potential for reduced follow up resulting in lower overall costs.

Table of Contents

## Results of Operations

## Operations Overview - Three and Nine Months Ended September 30, 2012 versus 2011

The following table presents our results of continuing operations and the related percentage of the period's revenue (in thousands):

|  | Three Months Ended September 30, |         |      |            | Nine Months Ended September 30, |   |             |         |   |             |         |   |
|--|----------------------------------|---------|------|------------|---------------------------------|---|-------------|---------|---|-------------|---------|---|
|  | 2012                             |         | 2011 |            | 2012                            |   | 2011        |         |   |             |         |   |
| Revenue  | \$26,696                         | 100.0   | %    | \$22,302   | 100.0                           | % | \$76,725    | 100.0   | % | \$60,025    | 100.0   | % |
| Cost of goods sold                                     | 6,444                            | 24.1    | %    | 4,829      | 21.7                            | % | 18,148      | 23.7    | % | 13,352      | 22.2    | % |
| Gross profit   | 20,252                           | 75.9    | %    | 17,473     | 78.3                            | % | 58,577      | 76.3    | % | 46,673      | 77.8    | % |
| Operating expenses:                                    |                                  |         |      |            |                                 |   |             |         |   |             |         |   |
| Research and development                               | 3,076                            | 11.5    | %    | 3,628      | 16.3                            | % | 11,886      | 15.5    | % | 12,812      | 21.3    | % |
| Clinical and regulatory affairs                        | 1,462                            | 5.5     | %    | 1,179      | 5.3                             | % | 4,727       | 6.2     | % | 2,994       | 5.0     | % |
| Marketing and sales                                    | 12,705                           | 47.6    | %    | 12,331     | 55.3                            | % | 38,923      | 50.7    | % | 33,201      | 55.3    | % |
| General and administrative                             | 4,942                            | 18.5    | %    | 4,184      | 18.8                            | % | 13,813      | 18.0    | % | 11,087      | 18.5    | % |
| Contract termination and business acquisition expenses | —                                | —       | %    | 1,300      | 5.8                             | % | 422         | 0.6     | % | 1,730       | 2.9     | % |
| Settlement costs                                       | 5,000                            | 18.7    | %    | —          | —                               | % | 5,000       | 6.5     | % | —           | —       | % |
| Total operating expenses                               | 27,185                           | 101.8   | %    | 22,622     | 101.4                           | % | 74,771      | 97.5    | % | 61,824      | 103.0   | % |
| Loss from operations                                   | (6,933 )                         | (26.0 ) | %    | (5,149 )   | (23.1 )                         | % | (16,194 )   | (21.1 ) | % | (15,151 )   | (25.2 ) | % |
| Total other income (expense)                           | 923                              | 3.5     | %    | (1,454 )   | (6.5 )                          | % | (12,765 )   | (16.6 ) | % | (9,913 )    | (16.5 ) | % |
| Net loss before income tax expense                     | (6,010 )                         | (22.5 ) | %    | (6,603 )   | (29.6 )                         | % | (28,959 )   | (37.7 ) | % | (25,064 )   | (41.8 ) | % |
| Income tax (expense) benefit                           | 153                              | 0.6     | %    | —          | —                               | % | (297 )      | (0.4 )  | % | —           | —       | % |
| Net loss   | \$(5,857 )                       | (21.9 ) | %    | \$(6,603 ) | (29.6 )                         | % | \$(29,256 ) | (38.1 ) | % | \$(25,064 ) | (41.8 ) | % |

## Comparison of the Three Months Ended September 30, 2012 versus 2011

## Revenue

|         | Three Months Ended September 30, |          |          |                |
|---------|----------------------------------|----------|----------|----------------|
|         | 2012                             | 2011     | Variance | Percent Change |
|         | (in thousands)                   |          |          |                |
| Revenue | \$26,696                         | \$22,302 | \$4,394  | 19.7 %         |

Our 19.7% revenue increase of \$4.4 million over the prior year period resulted from:

(i) \$1.0 million increase in U.S. sales due to (a) the expansion of our U.S. sales force through the addition of clinical specialists that exclusively provide field support to our sales representatives, increasing overall sales force productivity, and (b) the continued adoption of AFX which was launched in the U.S. in August 2011;

(ii) \$1.5 million increase in European sales due to our transition from a significant third-party distributor to a more effective direct sales organization beginning in September 2011; and

Table of Contents

(iii) \$1.9 million increase in ROW sales due to improved market penetration by our international distributors, particularly in South America. In addition, ROW sales growth was aided by the July 2010 launch of AFX in Brazil and Argentina, and IntuiTrak orders by our distributor in Japan (in anticipation of Japanese regulatory approval), beginning in March 2012.

During the three months ended September 30, 2012, our European sales were derived from (i) our developing direct European sales force (including dedicated agents), serving the markets of Austria, Belgium, the Czech Republic, Denmark, France, Germany, Italy (beginning July 2, 2012), Luxembourg, the Netherlands, Romania, Sweden, Switzerland, and the United Kingdom (excluding Northern Ireland), and (ii) five independent distributors serving the markets in Italy (through June 30, 2012), Greece, Turkey, Poland, and Ireland. For the three months ended September 30, 2011, our European sales were solely derived from independent distributors. Our direct sales force in Europe began operations in September 2011.

## Cost of Goods Sold, Gross Profit, and Gross Margin

|  | Three Months Ended<br>September 30, |          | Variance | Percent<br>Change |   |
|--|-------------------------------------|----------|----------|-------------------|---|
|  | 2012                                | 2011     |          |                   |   |
|  | (in thousands)                      |          |          |                   |   |
| Cost of goods sold   | \$ 6,444                            | \$ 4,829 | \$ 1,615 | 33.4              | % |
| Gross profit   | 20,252                              | 17,473   | 2,779    | 15.9              | % |
| Gross margin percentage (gross profit as a percent of revenue) | 75.9                                | % 78.3   | % (2.4   | )%                |   |

The \$1.6 million increase in cost of goods sold was driven by our revenue increase of \$4.4 million.

Gross margin for the three months ended September 30, 2012 decreased to 75.9% from 78.3% for the three months ended September 30, 2011. This decrease is primarily due to (i) royalty expenses which were not present in the prior year period and (ii) an 11.6% decline in the value of the Euro relative to the U.S. dollar. These decreases were partially offset by a greater proportion of our current period revenue derived from our direct sales force, as opposed to distributor sales.

## Operating Expenses

|  | Three Months Ended September<br>30, |          | Variance | Percent<br>Change |    |
|--|-------------------------------------|----------|----------|-------------------|----|
|  | 2012                                | 2011     |          |                   |    |
|  | (in thousands)                      |          |          |                   |    |
| Research and development                               | \$ 3,076                            | \$ 3,628 | \$ (552  | ) (15.2           | )% |
| Clinical and regulatory affairs                        | 1,462                               | 1,179    | 283      | 24.0              | %  |
| Marketing and sales                                    | 12,705                              | 12,331   | 374      | 3.0               | %  |
| General and administrative                             | 4,942                               | 4,184    | 758      | 18.1              | %  |
| Contract termination and business acquisition expenses | —                                   | 1,300    | (1,300   | ) (100.0          | )% |
| Settlement costs                                       | 5,000                               | —        | 5,000    | 100.0             | %  |

Research and Development. The \$0.6 million decrease in research and development expenses was primarily driven by decreasing Ventana development activities, as the device reaches the final stages of development and progresses towards production and commercialization.

Clinical and Regulatory Affairs. The \$0.3 million increase in clinical affairs was primarily driven by the continued enrollment and follow-up costs associated with our Ventana clinical trial and our efforts to achieve CE Mark approval

of the Ventana and Nellix devices.

Marketing and Sales. The \$0.4 million increase in marketing and sales expenses for the three months ended September 30, 2012, as compared to the prior year period, was primarily related to marketing costs to support the growth of our U.S. business, and costs related to our direct sales force in Europe (which was largely not present in the prior year period), offset by a decrease in variable compensation expense of \$0.9 million in the U.S.

22

---

Table of Contents

We expect that sales and marketing expense will remain significantly above prior year amounts due to the continued expansion of our U.S. and European sales forces.

General and Administrative. The \$0.8 million increase in general and administrative expenses is attributable to (i) additional personnel to support our business growth; (ii) increased travel expenses associated with, and leading to, the expansion of our European operations; and (iii) professional service fees to develop our global legal structure.

Contract Termination and Business Acquisition Expenses. In the prior year period we early terminated our distribution agreement with our former pan-European distributor in return for a \$1.3 million termination fee. This early termination allowed us to begin selling our products in most of western Europe through our direct sales force, beginning September 1, 2011.

Settlement Costs. Settlement costs of \$5.0 million in the current period represents our accrual to settle a patent dispute with Cook Incorporated (see Note 8 to our accompanying Condensed Consolidated Financial Statements).

Provision for Income Taxes

|                    | Three Months Ended September |      |          |
|--------------------|------------------------------|------|----------|
|                    | 30,<br>2012                  | 2011 | Variance |
|                    | (in thousands)               |      |          |
| Income tax benefit | \$ 153                       | \$ — | \$ 153   |

Our income tax benefit was \$0.2 million and our effective tax rate was (2.5)% for the three months ended September 30, 2012. During the third quarter of 2012, we made adjustments to our estimate of income tax payable for 2012, which had the effect of reducing our income tax provision in the current period. During the three months ended September 30, 2012, we had operating legal entities in the U.S., Italy, and the Netherlands (including registered sales branches in certain countries in Europe). We had a single operating legal entity in the U.S. during the prior year period until September 2011, when we formed operating legal entities in the Netherlands to begin direct sales activity in Europe.

Comparison of the Nine Months Ended September 30, 2012 versus 2011

Revenue

|         | Nine Months Ended September |           |           |                   |
|---------|-----------------------------|-----------|-----------|-------------------|
|         | 30,<br>2012                 | 2011      | Variance  | Percent<br>Change |
|         | (in thousands)              |           |           |                   |
| Revenue | \$ 76,725                   | \$ 60,025 | \$ 16,700 | 27.8 %            |

Our 27.8% revenue increase of \$16.7 million over the prior year period resulted from:

(i) \$11.4 million increase in U.S. sales due to the (a) expansion of our U.S. sales force through the addition of clinical specialists that exclusively provide field support to our sales representatives, increasing overall sales force productivity and (b) the continued adoption of AFX which was launched in the U.S. in August 2011;

(ii) \$3.0 million increase in European sales due to our transition from a significant third-party distributor to a more effective direct sales organization beginning in September 2011; and

(iii) \$2.3 million increase in ROW sales due to improved market penetration by our international distributors, particularly in South America. In addition, ROW sales growth was aided by the July 2012 launch of AFX in Brazil and Argentina, and IntuiTrak orders by our distributor in Japan (in anticipation of Japanese regulatory approval), beginning in March 2012.

During the nine months ended September 30, 2012, our European sales were derived from (i) our developing direct European sales force (including dedicated agents), serving the markets of Austria, Belgium, the Czech Republic, Denmark, France, Germany, Italy (beginning July 2, 2012), Luxembourg, the Netherlands, Romania, Sweden, Switzerland, and the United Kingdom (excluding Northern Ireland), and (ii) five independent distributors serving the markets in Italy (through June 30,

Table of Contents

2012), Greece, Turkey, Poland, and Ireland. For the nine months ended September 30, 2011, our European sales were solely derived from independent distributors.

## Cost of Goods Sold, Gross Profit, and Gross Margin

|  | Nine Months Ended<br>September 30, |           | Variance | Percent<br>Change |   |
|--|------------------------------------|-----------|----------|-------------------|---|
|  | 2012                               | 2011      |          |                   |   |
|  | (in thousands)                     |           |          |                   |   |
| Cost of goods sold   | \$ 18,148                          | \$ 13,352 | \$ 4,796 | 35.9              | % |
| Gross profit   | 58,577                             | 46,673    | 11,904   | 25.5              | % |
| Gross margin percentage (gross profit as a percent of revenue) | 76.3                               | % 77.8    | % (1.5   | )%                |   |

The \$4.8 million increase in cost of goods sold was driven by our revenue increase of \$16.7 million.

Gross margin for the nine months ended September 30, 2012 decreased to 76.3% from 77.8% for the nine months ended

September 30, 2011. This decrease is primarily due to (i) royalty expenses which were not present in the prior year period and

(ii) an 8.9% decline in the value of the Euro relative to the U.S. dollar. These decreases were partially offset by a greater proportion of our current period revenue derived from our direct sales force, as opposed to distributor sales.

## Operating Expenses

|  | Nine Months Ended September<br>30, |           | Variance | Percent<br>Change |    |
|--|------------------------------------|-----------|----------|-------------------|----|
|  | 2012                               | 2011      |          |                   |    |
|  | (in thousands)                     |           |          |                   |    |
| Research and development                               | \$ 11,886                          | \$ 12,812 | \$(926   | ) (7.2            | )% |
| Clinical and regulatory affairs                        | 4,727                              | 2,994     | 1,733    | 57.9              | %  |
| Marketing and sales                                    | 38,923                             | 33,201    | 5,722    | 17.2              | %  |
| General and administrative                             | 13,813                             | 11,087    | 2,726    | 24.6              | %  |
| Contract termination and business acquisition expenses | 422                                | 1,730     | (1,308   | ) (75.6           | )% |
| Settlement costs                                       | 5,000                              | —         | 5,000    | 100.0             | %  |

Research and Development. The \$0.9 million decrease in research and development expenses was primarily driven by decreasing Ventana development activities, as this device reaches the final stages of development and progresses towards production and commercialization. This decrease was partially offset by a \$1.0 million purchase in the current period (accounted for as an expense) for an exclusive license to patents covering the polymer used in our Nellix Device.

Clinical and Regulatory Affairs. The \$1.7 million increase in clinical affairs was primarily driven by the continued enrollment and follow-up costs associated with our PEVAR and Ventana clinical trials and our efforts to achieve CE Mark approval of Ventana and the Nellix Device.

Marketing and Sales. The \$5.7 million increase in marketing and sales expenses for the nine months ended September 30, 2012, as compared to the prior year period, was primarily related to marketing costs to support the growth of our U.S. business, costs related to our direct sales force in Europe (which was largely not present in the prior year period), and an increase in variable compensation expense of \$0.9 million, driven by an increase in U.S. revenue of 27.8%.

General and Administrative. The \$2.7 million increase in general and administrative expenses is attributable to (i) additional personnel to support our business growth; (ii) increased travel expenses associated with the expansion of our European operations; and (iii) professional service fees to develop our global legal structure.

Contract Termination and Business Acquisition Expenses. Current period expense of \$0.4 million is associated with professional fees incurred as part of the July 2012 acquisition of our Italian distributor's business. In the prior year period we early terminated a distribution agreement with two former European distributors for aggregate termination fees of \$1.7 million. These actions allowed us to begin selling our products through our direct sales force in most of western Europe, beginning September 1, 2011, and in Italy, beginning July 2, 2012.

Table of Contents

Settlement Costs. Settlement costs of \$5.0 million in the current period represents our accrual to settle a patent dispute with Cook Incorporated.

## Provision for Income Taxes

|                    | Nine Months Ended September 30, |      |          |
|--------------------|---------------------------------|------|----------|
|                    | 2012                            | 2011 | Variance |
|                    | (in thousands)                  |      |          |
| Income tax expense | \$297                           | \$—  | \$297    |

For the nine months ended September 30, 2012, our provision for income taxes was \$0.3 million and our effective tax rate was 1.0% for the nine months ended September 30, 2012. During the nine months ended September 30, 2012, we had operating legal entities in the U.S., Italy, and the Netherlands (including registered sales branches in certain countries in Europe). We had a single operating legal entity in the U.S. during the prior year period until September 2011, when we formed operating legal entities in the Netherlands to begin direct sales activity in Europe.

## Liquidity and Capital Resources

The chart provided below summarizes selected liquidity data and metrics as of September 30, 2012, December 31, 2011, and September 30, 2011:

|                                    | September 30,<br>2012                         | December 31,<br>2011 | September 30,<br>2011 |
|------------------------------------|---|----------------------|-----------------------|
|                                    | (in thousands, except financial metrics data) |                      |                       |
| Cash and cash equivalents          | \$47,740                                      | \$20,035             | \$23,872              |
| Accounts receivable, net           | \$19,616                                      | \$15,542             | \$16,267              |
| Total current liabilities          | \$18,728                                      | \$13,949             | \$15,127              |
| Working capital surplus (a)        | \$69,570                                      | \$41,155             | \$41,930              |
| Days sales outstanding ("DSO") (b) | 68  | 68                   | 67                    |
| Current ratio (c)                  | 4.71  | 3.95                 | 3.77                  |

(a) total current assets minus total current liabilities.

(b) net accounts receivable divided by the quarter's net revenue, then multiplied by 92 days.

(c) total current assets divided by total current liabilities.

## Operating Activities

Cash used in operating activities was \$12.2 million for the nine months ended September 30, 2012, as compared to cash used in operating activities of \$17.6 million in the prior year period. The decrease in cash used in operating activities is primarily a function of particularly large inventory expenditures in the prior year period to prepare for our August 2011 launch of AFX.

During the nine months ended September 30, 2012 and 2011, our cash collections from customers totaled \$72.7 million and \$56.2 million, respectively, representing 94.7% and 93.6% of reported revenue for the same periods.

## Investing Activities

Cash used in investing activities for the nine months ended September 30, 2012 was \$3.9 million and consisted of (i) machinery and equipment purchases for the production of our ELG Systems; (ii) expenditures for various information technology enhancements; and (iii) our acquisition of our former Italian distributor's business.

## Financing Activities

Cash provided by financing activities was \$43.8 million for the nine months ended September 30, 2012, as compared to cash provided by financing activities of \$5.0 million in the prior year period. The \$43.8 million of cash provided by financing activities was attributable to our (i) \$40.1 million of net proceeds from the June 2012 Equity Raise (discussed below); (ii) proceeds of \$2.4 million from the exercise of stock options; and (iii) proceeds of \$1.4 million from our sale of stock through our employee stock purchase plan.

## June 2012 Equity Raise



## Table of Contents

On May 30, 2012, we executed a common stock purchase agreement (the "Stock Purchase Agreement") with Piper Jaffray & Co. ("Piper"). As part of the Stock Purchase Agreement Piper purchased 2.7 million shares of our common stock at \$13.00 per share on June 5, 2012, and subsequently executed an option to purchase an additional 0.4 million shares at \$13.00 per share, which closed on June 7, 2012.

These two transactions resulted in net proceeds to us of \$40.1 million (the "June 2012 Equity Raise"). We plan to use these proceeds to support our continued growth, which may include sales and marketing expenditures, research and development activities, clinical trials, business expenditures, and administrative and infrastructure investments.

### Credit Arrangements

In October 2009, we entered into a revolving credit facility with Wells Fargo Bank ("Wells"), which was last amended on October 9, 2012, whereby we may borrow up to \$20.0 million, subject to the calculation and limitation of a borrowing base (the "Wells Credit Facility"). All amounts owing under the Wells Credit Facility will become due and payable upon its expiration on March 31, 2013. As of September 30, 2012, we did not have any outstanding borrowings under the Wells Credit Facility. Any outstanding amounts under the Wells Credit Facility bear interest at a variable rate equal to the Wells prime rate, plus 1.00%, which is payable on a monthly basis. The Wells Credit Facility is collateralized by all of our assets, except its intellectual property.

The Wells Credit Facility contains financial covenants requiring us to (i) maintain a minimum current ratio of 1.5, equal to the quotient of modified current assets to current liabilities, as defined in the Wells Credit Facility (the "Current Ratio Covenant"), and (ii) not exceed operating loss amounts (excluding non-cash contingent consideration associated with the acquisition of Nellix) of \$6.5 million for the quarter ended March 31, 2012; \$11.0 million for the six months ended June 30, 2012; \$13.0 million for the nine months ended September 30, 2012; and \$13.0 million for the year ended December 31, 2012 (the "Operating Loss Covenant"). The Wells Credit Facility carried a 0.2% unused commitment fee through May 19, 2012, when this fee was eliminated. The Wells Credit Facility also includes a negative covenant limiting 2012 capital expenditures to an aggregate \$3.0 million.

We were not in compliance with the Operating Loss Covenant for the nine months ended September 30, 2012. We obtained a waiver for the breach of the Operating Loss Covenant from Wells on October 26, 2012, whereby Wells agreed to forbear from enforcing their default rights under the Wells Credit Facility. The waiver does not apply to any subsequent breaches of the same provision, nor any breach of any other provision specified within the Wells Credit Facility.

The Wells Credit Facility also contains a "material adverse change" clause ("MAC"). If we encounter difficulties that would qualify as a MAC in its (i) operations, (ii) condition (financial or otherwise), or (iii) ability to repay amounts outstanding under the Wells Credit Facility, it could be canceled at Wells' sole discretion. Wells could then elect to declare the indebtedness, together with accrued interest and other fees, to be immediately due and payable and proceed against any collateral securing such indebtedness.

### Credit Risk

The majority of our accounts receivable arise from product sales in the U.S. However, we also have significant receivable balances from customers within the European Union, Japan, Brazil, Argentina, and Mexico. Our accounts receivable in the U.S. are primarily due from public and private hospitals. Our accounts receivable outside of the U.S. are primarily due from independent distributors, and to a lesser extent, public and private hospitals. Our historical write-offs of accounts receivable have not been significant.

We monitor the financial performance and credit worthiness of our customers so that we can properly assess and respond to changes in their credit profile. Since our customers operate in certain countries such as Greece, where adverse economic conditions persist, it increases the risk of our inability to collect amounts due to us from them. To

determine our allowance for doubtful accounts we consider these factors and other relevant considerations. Our allowance for doubtful accounts of \$0.2 million as of September 30, 2012, represents our best estimate of the amount of probable credit losses in our existing accounts receivable.

#### Future Capital Requirements

We believe that the future growth of our business will depend upon our ability to successfully develop new technologies for the treatment of aortic disorders and successfully bring these technologies to market. We expect to incur significant expenditures in completing product development and clinical trials for Ventana and the Nellix Device.

## Table of Contents

The timing and amount of our future capital requirements will depend on many factors, including:

- the need for working capital to support our sales growth;
- the need for additional capital to fund future development programs;
- the need for additional capital to fund our sales force expansion;
- the need for additional capital to fund strategic acquisitions;
- our requirements for additional facility space or manufacturing capacity;
- our requirements for additional information technology infrastructure and systems; and
- adverse outcomes from potential litigation and the cost to defend such litigation.

We believe that our cash resources are adequate to operate our business. We expect to generate positive cash flows from operations before the end of 2012. In the event we require additional financing in the future, it may not be available on commercially reasonable terms, if possible at all. Even if we are able to obtain financing, it may cause substantial dilution (in the case of an equity financing), or may contain burdensome restrictions on the operation of our business (in the case of debt financing). If we are not able to obtain required financing, we may need to curtail our operations and/or our planned product development.

### Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements (except operating leases) that provide financing, liquidity, market or credit risk support, or involve derivatives. In addition, we have no arrangements that may expose us to liability that is not expressly reflected in the accompanying Condensed Consolidated Financial Statements.

As of September 30, 2012, we did not have any relationships with unconsolidated entities or financial partnerships, often referred to as "structured finance" or "special purpose entities," established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. As such, we are not subject to any material financing, liquidity, market or credit risk that could arise if we had engaged in such relationships.

### Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

We do not believe that we currently have material exposure to interest rate, foreign currency exchange rate or other relevant market risks.

**Interest Rate and Market Risk.** Our exposure to market risk for changes in interest rates relates primarily to the Wells Credit Facility. All outstanding amounts under the Wells Credit Facility bear interest at a variable rate equal to the Wells prime rate, plus 1.00%, which is payable on a monthly basis. As of September 30, 2012, we had no amounts outstanding under the Wells Credit Facility. However, if we draw down the Wells Credit Facility, we may be exposed to market risk due to changes in the rate at which interest accrues.

We do not use derivative financial instruments in our investment portfolio. We are averse to principal loss and try to ensure the safety and preservation of our invested funds by limiting default risk, market risk, and reinvestment risk. We attempt to mitigate default risk by investing in only high credit quality securities and by positioning our portfolio to appropriately respond to a significant reduction in the credit rating of any investment issuer or guarantor. At September 30, 2012, our investment portfolio solely consisted of money market instruments.

**Foreign Currency Transaction Risk.** While a majority of our business is denominated in the United States dollar, a portion of our revenues and expenses are denominated in foreign currencies. Fluctuations in the rate of exchange between the U.S. dollar and the Euro or the British Pound Sterling may affect our results of operations and the period-to-period comparisons of our operating results.

Item 4. CONTROLS AND PROCEDURES.

Our management carried out an evaluation, under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, of the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report, pursuant to Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on that evaluation, our chief executive officer and chief financial officer have concluded that our disclosure controls and procedures, as of the end of the period covered by this report, were effective to ensure that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and to ensure that information required to be disclosed by us in the reports that we file or

27

---

Table of Contents

submit under the Exchange Act is accumulated and communicated to our management, including our chief executive officer and chief financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

There has been no change in our internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) during the third quarter of 2012 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

Part II.

OTHER INFORMATION

Item 1. LEGAL PROCEEDINGS.

We are from time to time involved in various claims and legal proceedings of a nature we believe are normal and incidental to a medical device business. These matters may include product liability, intellectual property, employment, and other general claims. We accrue for contingent liabilities when it is probable that a liability has been incurred and the amount can be reasonably estimated. The accruals are adjusted periodically as assessments change or as additional information becomes available.

Cook Incorporated v. Endologix, Inc.

We had been involved in litigation with Cook Incorporated (“Cook”). Cook alleged that we infringed two of its patents, granted in 1991 and 1998, which expired on October 17, 2009 and October 25, 2011, respectively (the "Patent Dispute"). The lawsuit was filed by Cook in the U.S. District Court for the Southern District of Indiana (the "Court"), on October 8, 2009.

On October 16, 2012, we entered into a Settlement Agreement with Cook for the Patent Dispute (the “Settlement Agreement”), which included a full release of all asserted claims. Without admitting any liability, we agreed to make a one-time cash payment to Cook of \$5.0 million, which is expected to occur in November 2012.

The Company's accrual for the \$5.0 million settlement value is presented within operating expenses as settlement costs for the three and nine months ended September 30, 2012 of the accompanying Condensed Consolidated Statements of Operations.

Item 6. EXHIBIT INDEX.

The following exhibits are filed or furnished herewith:

|                 |  |
|-----------------|--|
| Exhibit 10.1    | Form of Employee Restricted Stock Unit Award Agreement under 2006 Stock Incentive Plan.  |
| Exhibit 10.2    | Form of Director Restricted Stock Unit Award Agreement under 2006 Stock Incentive Plan.  |
| Exhibit 31.1    | Certification of Chief Executive Officer Pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934.                            |
| Exhibit 31.2    | Certification of Chief Financial Officer Pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934.                            |
| Exhibit 32.1    | Certification of Chief Executive Officer Pursuant to Rule 13a-14(b)/15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350. |
| Exhibit 32.2    | Certification of Chief Financial Officer Pursuant to Rule 13a-14(b)/15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350. |
| Exhibit 101.INS | XBRL Instance Document   |
| Exhibit 101.SCH | XBRL Taxonomy Extension Schema Document  |
| Exhibit 101.CAL | XBRL Taxonomy Extension Calculation Lin Base Document  |
| Exhibit 101.DEF | XBRL Taxonomy Extension Definition Link Base Document  |

Exhibit 101.LAB XBRL Taxonomy Extension Label Link Base Document

Exhibit 101.PRE XBRL Taxonomy Extension Presentation Link Base Document

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ENDOLOGIX, INC.

October 31, 2012

/s/ John McDermott  
President and Chief Executive Officer

October 31, 2012

/s/ Robert J. Krist  
Chief Financial Officer and Secretary